Browsing by Author "Xiu, Joanne"
Now showing items 1-7 of 7
-
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
( Elsevier , 2018 , Article)Lungs are among the most common sites for development of both primary and metastatic carcinomas. Tumor cells expression (TC) of PD-L1 is an important predictor of the of response to immune check-point inhibition in NSCLC, ... -
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
( Elsevier Ltd , 2018 , Article)Background: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for ... -
Molecular characterization of cancers with NTRK gene fusions
( Springer Nature , 2019 , Article)Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently detected in rare cancer types (e.g., secretory ... -
Molecular profiling of the metaplastic spindle cell carcinoma of the breast reveals potentially targetable biomarkers
( Elsevier , 2020 , Article)IntroductionSpindle cell carcinoma is a rare subtype of metaplastic breast cancer (MBC), with triple-negative (TNBC: ER-/PR-/Her2-) phenotype. It is associated with a marked resistance to conventional chemotherapy and has ... -
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
( Elsevier , 2018 , Article)Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new ... -
TERT gene fusions characterize a subset of metastatic Leydig cell tumors
( Elsevier , 2021 , Article)Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic ... -
Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast.
( Wiley , 2019 , Article)Pleomorphic ductal carcinoma (PDC) is a very rare subtype of invasive ductal carcinoma of no‐special type (NST), characterized by the presence of highly atypical/bizarre (>6‐fold variation in nuclear size) and multinucleated ...
